Venture Fund Member Profile
|
 |
 |
Pappas Ventures is a life sciences venture capital firm located in the Research Triangle area of North Carolina. Since 1994 we have been investing in and nurturing promising young companies, while delivering superior results to investors and entrepreneurs alike. We have $230 million in capital under management and have invested in more than 30 portfolio companies throughout the United States. We invest exclusively in the life science sector – biotechnology, biopharmaceuticals, specialty pharmaceuticals, drug delivery, and medical devices.
|
Art Pappas
Managing Partner
Pappas Ventures |
Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts who manage over $350 million and oversee investments in more than 40 portfolio companies. Prior to founding Pappas Ventures in 1994, Art held senior level leadership positions at several multinational pharmaceutical companies. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was the chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Among the companies for which he currently serves as a director are: CeNeRx BioPharma, Genstruct, LEAD Therapeutics and TyRx Pharma. He was the founding CEO and is currently the chairman of CoLucid Pharmaceuticals.
Some of the firm's representative investments include Cerexa Pharmaceuticals (acquired by Forest Laboratories); Syntonix Pharmaceuticals (acquired by Biogen Idec); Peninsula Pharmaceuticals (acquired by Johnson & Johnson); Panacos Pharmaceuticals (Nasdaq: PANC); NuVasive (Nasdaq: NUVA); Gene Logic (Nasdaq: GLGC); Nuvelo (Nasdaq: NUVO; previously Variagenics); and Arena Pharmaceuticals (Nasdaq: ARNA).
Art is chairman of the North Carolina Biotechnology Center's Board of Directors and is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board. He previously served on the boards of AtheroGenics (Nasdaq: AGIX), Embrex (Nasdaq: EMBX), Quintiles Transnational (Nasdaq: QTRN) and Valentis (Nasdaq: VLTS). Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and the Special Forces.
Representative Investments
 |
Cerexa, Inc. Cerexa, Inc. is a privately owned biopharmaceutical company focused on acquiring, developing, and commercializing hospital-based anti-infective therapies for the treatment of patients with serious, life-threatening infections. The Company was formed in the Spring of 2005 as a spin-out from Peninsula Pharmaceuticals in preparation for the acquisition of Peninsula by Johnson & Johnson. |
 |
Genstruct Systems biology drug discovery company that deploys its mechanism discovery platform, Molecular EpistemicsTM, independently and in partnerships with pharmaceutical companies to streamline drug discovery and improve clincial trial design and implementation. Pappas Ventures II originally invested in Incellico, Inc. which was acquired in July 2003 by Genstruct. |
 |
Plexigen Company developing an innovative, proprietary 3-D biochip to significantly enhance the capacity, efficiency, accuracy and automation of gene screening. The technology was originally developed at North Carolina State University. |
 |
Sensys Medical Developer of non-invasive technology for blood glucose monitoring. Once cleared by the Food and Drug Administration, the technology will provide a painless method to collect data for proactive use in controlling diabetes. |
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
